Biology Reference
In-Depth Information
[120] Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, et al. Lenalidomide enhances
natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of
rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008;14(14):4650-7.
[121] Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, et al. Lenalidomide
down-regulates the CD20 antigen and antagonizes direct and antibody-dependent
cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood
2008;112(13):5180-9.
[122] Wu L, Parton A, Lu L, Adams M, Schafer P, Bartlett JB. Lenalidomide enhances
antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host
immune and tumor markers. Cancer Immunol Immunother 2011;60(1):61-73.
[123] Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, et al. The
activation of natural killer cell effector functions by cetuximab-coated, epidermal
growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res
2007;13(21):6419-28.
[124] Kipriyanov SM, Cochlovius B, Schäfer HJ, Moldenhauer G, Bähre A, Le Gall F, et al.
Synergistic antitumor effect of bispecific CD19 × CD3 and CD19 × CD16 diabodies in a
preclinical model of non-Hodgkin's lymphoma. J Immunol 2002;169(1):137-44.
[125] Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, et al. Sensitiza-
tion of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol
2008;180(1):163-70.
[126] Yong AS, Keyvanfar K, Hensel N, Eniafe R, Savani BN, Berg M, et al. Primitive quiescent
CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural
killer cells, which are functionally enhanced by bortezomib. Blood 2009;113(4):875-82.
[127] Lundqvist A, Abras SI, Schrump DS, Alvarez G, Suffredini D, Berg M, et al. Bortezomib
and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing
ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res
2006;66(14):7317-25.
[128] Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U,
Langenkamp U, et al. NKG2D ligand expression in AML increases in response to HDAC
inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single
KIR-HLA class I specificities. Blood 2008;111(3):1428-36.
[129] Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy
of human glioma by means of a genetically engineered virus mutant. Science
1991;252(5007):854-6.
[130] Orange JS. Human natural killer cell deficiencies and susceptibility to infection. Mi-
crobes Infect 2002;4(15):1545-58.
[131] Baraz L, Khazanov E, Condiotti R, Kotler M, Nagler A. Natural killer (NK) cells prevent
virus production in cell culture. Bone Marrow Transplant 1999;24(2):179-89.
[132] Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, et al. Onco-
lytic virus therapy of multiple tumors in the brain requires suppression of innate and
elicited antiviral responses. Nat Med 1999;5(8):881-7.
[133] Bergmann M, Romirer I, Sachet M, Fleischhacker R, Garcia-Sastre A, Palese P, et al.
A genetically engineered influenza A virus with ras-dependent oncolytic properties.
Cancer Res 2001;61(22):8188-93.
[134] Ogbomo H, Michaelis M, Geiler J, van Rikxoort M, Muster T, Egorov A, et al. Tumor cells
infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant
tumor cells. Med Microbiol Immunol 2010;199(2):93-101.
[135] Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bed-
side. Clin Microbiol Rev 2009;22(1):76-98.
[136] Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M,
et al. Early human cytomegalovirus replication after transplantation is associated with
a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute
myeloid leukemia patients. Blood 2011;118(5):1402-12.
[137] Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA, et al. Alloge-
neic hematopoietic cell transplantation for hematologic malignancy: relative risks and
benefits of double umbilical cord blood. Blood 2010;116(22):4693-9.
356
Search WWH ::
Custom Search